Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AIP Therapeutics
Seoul, South Koreaaip-tx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AIP Therapeutics is a South Korean biotechnology company specializing in the development of small molecule therapeutics that target the Aryl Hydrocarbon Receptor (AhR) pathway. The company's research focuses on the AIP-AhR axis to modulate immune responses, offering potential treatments for both oncology and autoimmune diseases. Their lead candidate, AIP-101, is an AhR agonist currently in clinical development for the treatment of atopic dermatitis. By leveraging deep expertise in protein-protein interactions within the AhR complex, AIP Therapeutics seeks to address significant unmet needs in immunology and oncology through precision modulation of immune homeostasis.
- Therapeutic areas
- OncologyDermatologyGastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Seoul National University
Beyond the preview
Go deeper on AIP Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIP Therapeutics.